Benign Prostatic Enlargement: Non-Cancerous Growth of the Prostate

Benign prostatic enlargement is a common age related increase in prostate size that can affect urine flow and bladder function. It is not prostate cancer and does not become cancer, although both conditions can coexist. Assessment identifies the symptom pattern, excludes complications and cancer warning signs, and guides lifestyle, medicine or procedural treatment.

What benign prostatic enlargement is Benign prostatic enlargement, shortened to BPE, means non cancerous enlargement of the prostate gland. The underlying microscopic process is usually benign prostatic hyperplasia, involving increased numbers of glandular and smooth muscle cells. The enlarging tissue can narrow the urethra and increase resistance to urine leaving the bladder. Some enlarged prostates cause major symptoms, while others cause no noticeable urinary difficulty. Where the prostate is The prostate sits below the bladder and surrounds the first part of the urethra. The urethra is the tube carrying urine from the bladder through the penis and outside the body. The prostate also contributes fluid to semen and normally increases gradually in size with age. Its position explains why enlargement can affect both urine flow and bladder function. BPH, BPE and BPO Benign prostatic hyperplasia, or BPH, describes the microscopic increase in prostate cells. Benign prostatic enlargement, or BPE, describes an increase in the gland's overall size. Benign prostatic obstruction, or BPO, means the enlargement or muscle tone is actually obstructing urine flow. These terms overlap but are not identical, because enlargement does not always produce obstruction or symptoms. How the prostate enlarges Most benign growth develops within the transition zone surrounding the urethra. Age related hormone signalling, particularly involving dihydrotestosterone, supports growth of prostate glandular and stromal tissue. Genetics, inflammation and other biological factors may also influence how enlargement develops. The process is common with ageing but does not occur identically in every person. Fixed and dynamic obstruction The physical bulk of enlarged prostate tissue creates a fixed component of urinary resistance. Smooth muscle tension within the prostate and bladder neck creates an additional dynamic component. Alpha blocker medicines mainly reduce the dynamic tension, while 5 alpha reductase inhibitors gradually reduce prostate volume. Understanding these components explains why different medicines act at different speeds. How the bladder responds The bladder muscle initially works harder to push urine through the narrowed outlet. This can cause thicker bladder muscle, urgency, frequency and unstable bladder contractions. Long standing obstruction can eventually weaken bladder contraction and leave increasing urine after voiding. Storage symptoms can therefore continue even after the prostate obstruction is treated successfully. Prostate size does not reliably predict symptoms A mildly enlarged prostate can cause troublesome obstruction when its shape narrows the urethra significantly. A much larger prostate can cause few symptoms when growth occurs mainly away from the urethra. Bladder sensitivity, muscle function, fluid production and other conditions also influence symptom severity. Treatment should therefore respond to symptoms, complications and findings rather than size alone. How common BPE is Benign enlargement becomes increasingly common after age 50 and is very common in older age groups. Many people have microscopic BPH without urinary symptoms or awareness of prostate enlargement. Family history can increase susceptibility, but it does not determine symptom severity or treatment need. Age related enlargement is common, but bothersome urinary symptoms should not simply be dismissed as ageing. BPE is not prostate cancer Benign prostatic enlargement is not caused by prostate cancer and is not a premalignant condition. Having BPE does not reliably predict a higher future risk of developing prostate cancer. However, BPE and prostate cancer can occur in the same person because both become common with age. New or changing symptoms still require appropriate assessment rather than automatic attribution to known BPE. Lower urinary tract symptoms Lower urinary tract symptoms, shortened to LUTS, describe difficulties involving urine storage, voiding or the period after voiding. LUTS do not prove that the prostate is enlarged or obstructing the bladder outlet. Bladder disease, infection, diabetes, medicines and neurological conditions can produce similar symptoms. Assessment identifies which symptom group dominates and whether complications or alternative causes are present. Voiding symptoms Voiding symptoms occur while starting or maintaining the urinary stream and emptying the bladder. They include hesitancy, weak flow, intermittent flow, straining, incomplete emptying and terminal dribbling. These symptoms can suggest bladder outlet obstruction but do not identify its cause by themselves. A urethral stricture, weak bladder muscle or prostate cancer can produce a similar pattern. Hesitancy Hesitancy means waiting longer than expected before the urine stream begins. A person may stand or sit for some time before urine starts despite feeling ready. Anxiety, pelvic floor tension, pain and unfamiliar surroundings can also delay starting the stream. Persistent hesitancy with other voiding symptoms warrants structured assessment. Weak urinary stream A weak stream has reduced force or travels a shorter distance than previously. The person may notice progressively slower emptying or prolonged time spent at the toilet. Perceived flow strength is subjective and does not measure obstruction accurately by itself. Specialist flow rate testing can provide objective information when needed. Intermittent stream An intermittent stream repeatedly stops and starts during one attempt to urinate. This can occur when outlet resistance is high or bladder contraction cannot be sustained. Abdominal straining may temporarily restart the flow without correcting the underlying problem. Severe intermittency can be associated with substantial residual urine. Straining Straining means using abdominal pressure to start or maintain urination. It can indicate obstruction or weak bladder muscle contraction. Regular forceful straining is not recommended because it does not treat the cause and may be ineffective. Assessment becomes more urgent when straining accompanies a palpable bladder, infections or worsening kidney function. Incomplete emptying A person may feel that urine remains after the stream has finished. This sensation can occur with or without a large measured post void residual volume. Some people need to urinate again shortly afterwards because the bladder did not empty fully. Significant chronic retention can occasionally be painless and recognised only after complications develop. Terminal and post micturition dribbling Terminal dribbling means the urinary stream slows into prolonged drops before urination finishes. Post micturition dribble means urine leaks after the person believes voiding has ended. Urine can remain within the urethra and leak during movement or after clothing is replaced. Urethral milking can help selected people empty the final urine from the urethra. Storage symptoms Storage symptoms occur while the bladder is filling rather than during urine flow. They include increased frequency, urgency, nocturia and urgency urinary incontinence. Prostate obstruction can trigger these symptoms, but overactive bladder may exist independently. Storage symptoms can remain after surgery when bladder changes have become established. Urinary frequency Urinary frequency means passing urine more often than is usual for that person. Frequent small volumes can reflect bladder overactivity, incomplete emptying, infection or high fluid intake. Large frequent volumes can suggest diabetes, diuretic use or another cause of excessive urine production. A frequency volume chart helps distinguish these patterns. Urinary urgency Urgency is a sudden compelling need to pass urine that is difficult to postpone. It can interfere with travel, work, exercise and confidence leaving home. Urgency can result from bladder overactivity, infection, bladder stones or outlet obstruction. New urgency with pain, fever or blood in urine requires further assessment. Urgency urinary incontinence Urgency incontinence means urine leaks before the person reaches a toilet after a sudden urge. The amount can range from a few drops to complete bladder emptying. This symptom can cause embarrassment and social withdrawal but is treatable. Containment products can provide temporary support while the cause and management plan are assessed. Nocturia Nocturia means waking from sleep to pass urine one or more times. It can result from reduced bladder capacity, incomplete emptying or excessive urine production overnight. Evening fluids, alcohol, diuretics, leg swelling, diabetes, heart failure and sleep apnoea can contribute. Prostate treatment alone may not resolve nocturia when another cause is dominant. Symptoms can affect quality of life LUTS can disrupt sleep, concentration, work, travel, exercise, relationships and sexual confidence. People may map every toilet before leaving home or reduce fluids excessively to avoid urgency. Repeated night time waking can increase fatigue and falls risk, particularly in older adults. Treatment decisions should consider daily impact rather than symptom count alone. LUTS have several possible causes Benign prostate enlargement is only one cause of lower urinary tract symptoms. Other possibilities include urinary infection, prostatitis, urethral stricture, bladder stones and prostate or bladder cancer. Diabetes, heart failure, constipation, neurological disease and sleep apnoea can contribute. Several conditions can coexist, so identifying one does not automatically explain every symptom. Medicines can worsen urinary symptoms Diuretics increase urine production and can worsen frequency or nocturia. Decongestants and some medicines with anticholinergic effects can worsen difficulty emptying the bladder. Opioids, antihistamines, antidepressants and medicines affecting nerve function can also contribute in selected people. Prescription, over the counter and herbal products should all be included during medication review. Acute urinary retention Acute urinary retention means suddenly being unable to pass urine despite a full bladder. It usually causes severe lower abdominal pain, distress and a tender swollen bladder. Triggers can include infection, constipation, surgery, alcohol, medicines or progression of obstruction. NICE recommends immediate bladder catheterisation because prolonged pressure can damage the bladder and kidneys. Chronic urinary retention Chronic retention develops gradually and may cause limited pain despite a very large bladder volume. Possible clues include weak flow, overflow leakage, bed wetting, recurrent infection or a palpable bladder. Back pressure can dilate the ureters and kidneys, causing hydronephrosis and impaired renal function. Chronic retention with kidney impairment requires prompt drainage and specialist management. Other possible complications Incomplete emptying increases the risk of recurrent urinary infection and bladder stone formation. Fragile enlarged prostate vessels can occasionally contribute to visible blood in urine. Long standing obstruction can damage bladder muscle and reduce the chance of complete recovery after treatment. Complicated LUTS requires specialist assessment rather than lifestyle advice alone. Initial clinical assessment Assessment begins with the duration, progression and effect of each urinary symptom. The clinician asks about pain, fever, visible blood, recurrent infection, retention and kidney related symptoms. Fluid intake, caffeine, alcohol, bowel habits, medicines, diabetes and neurological symptoms are reviewed. Prostate cancer risk, sexual function and the person's treatment priorities are also discussed. International Prostate Symptom Score The International Prostate Symptom Score, or IPSS, is a validated seven question symptom questionnaire. It covers incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores from zero to seven are described as mild, eight to nineteen as moderate and twenty to thirty five as severe. A separate quality of life question asks how the person feels about continuing with their current symptoms. What the IPSS can and cannot do The IPSS records baseline symptom burden and helps measure change after treatment. It does not diagnose benign prostate enlargement, measure prostate size or exclude cancer. A person with a modest total score can still have a concerning symptom such as visible haematuria. Clinical decisions combine the score with history, examination, tests, complications and personal priorities. Frequency volume chart A frequency volume chart records when fluids are consumed and when urine is passed. The person records each voided volume and episodes of urgency, leakage or night time waking. The chart can identify excessive evening intake, small bladder capacity or high overnight urine production. NICE recommends it for bothersome LUTS during initial and specialist assessment. Physical examination Initial assessment includes examination of the abdomen, external genitalia and prostate through the rectum. The abdomen is checked for a distended bladder, masses or signs of another condition. Genital examination can identify foreskin, urethral, testicular or skin problems contributing to symptoms. Blood pressure and neurological examination may be appropriate according to the presentation. Digital rectal examination A digital rectal examination, or DRE, allows the clinician to feel the back surface of the prostate. A benign enlarged prostate commonly feels smooth, symmetrical and firm or rubbery. A hard, nodular, irregular or distinctly asymmetrical prostate raises concern about malignancy. A normal or smoothly enlarged prostate is reassuring but cannot exclude prostate cancer conclusively. Limits of digital rectal examination The examiner can feel only the posterior surface and cannot measure total prostate volume precisely. Small or anterior cancers may not be detectable through the rectum. Prostate size estimates vary between examiners and should not be treated as exact measurements. DRE findings are interpreted with PSA, symptoms, risk factors and subsequent imaging when indicated. Urinalysis NICE recommends a urine dipstick test during initial LUTS assessment. It checks for blood, glucose, protein, leucocytes and nitrites. Abnormal results can suggest infection, diabetes, renal disease, stones or urinary tract malignancy. A normal dipstick does not identify BPE or exclude every important urinary condition. Renal function testing Creatinine and estimated glomerular filtration rate are not required routinely for uncomplicated LUTS. NICE recommends renal testing when impairment is suspected from features such as a palpable bladder or recurrent infections. Nocturnal enuresis, renal stone history and chronic retention can also justify testing. Abnormal renal function can prompt urgent drainage, upper tract imaging and specialist assessment. The PSA decision Prostate specific antigen, or PSA, is a protein produced by benign and malignant prostate tissue. NICE recommends providing information, advice and decision time before testing for selected people with LUTS. Testing is considered when symptoms suggest BPE related obstruction, the prostate feels abnormal or cancer concern exists. The person should understand possible benefits, limitations and consequences before the blood sample is taken. What PSA can show PSA can indicate that further prostate assessment may be appropriate. A raised result can occur with prostate cancer, BPE, prostatitis, infection or recent prostate disturbance. PSA can also provide indirect information about prostate size and progression risk during BPE assessment. It is one part of a diagnostic pathway rather than a cancer diagnosis by itself. What PSA cannot show PSA cannot determine by itself whether prostate cancer is present or absent. Many people with raised PSA do not have clinically significant cancer, creating false positive results. Some prostate cancers occur despite PSA remaining within the expected reference range, creating false negative results. A normal result should not override a malignant feeling prostate or concerning systemic symptoms. Factors that can temporarily raise PSA Urinary infection and prostatitis can raise PSA substantially through inflammation. Recent ejaculation and vigorous exercise, particularly cycling, can cause smaller temporary increases. Catheterisation, cystoscopy, prostate biopsy and other urinary instrumentation can also affect the result. Testing may need postponement or repetition after sufficient recovery from these factors. Preparing for a PSA test Urinary infection should be treated and resolved before PSA is interpreted for cancer risk. People are commonly advised to avoid ejaculation and vigorous exercise for 48 hours beforehand. Recent catheterisation, biopsy or bladder and prostate procedures should be reported to the clinician. All medicines must be disclosed because finasteride and dutasteride lower PSA concentrations. Interpreting a raised PSA The clinician considers age, prostate size, ethnicity, family history, medicines and previous PSA results. A raised result may be repeated when a temporary benign cause is likely and examination is reassuring. Persistent elevation above the relevant threshold can lead to a suspected cancer pathway referral. Specialist assessment commonly uses prostate MRI before deciding whether biopsy is required. Interpreting a low PSA A low or age appropriate PSA reduces concern but does not eliminate prostate cancer possibility. Referral remains appropriate when the prostate feels malignant regardless of the PSA result. Persistent bone pain, unexplained weight loss or neurological symptoms also require investigation despite a low PSA. Safety netting should explain which changing symptoms require reassessment. Specialist assessment Specialist assessment commonly includes urinary flow rate and post void residual urine measurement. Ultrasound can measure prostate volume, residual urine and upper tract dilation when clinically indicated. Cystoscopy is reserved for concerns such as haematuria, recurrent infection, pain or possible urethral disease. Urodynamic testing can clarify bladder function before selected surgical decisions. BPE and prostate cancer can coexist BPE usually arises centrally around the urethra, while many prostate cancers begin in the peripheral zone. This anatomical difference partly explains why cancer can exist without producing early urinary obstruction. Urinary symptoms alone cannot reliably distinguish benign enlargement from cancer. Assessment focuses on cancer warning signs without presenting ordinary LUTS as proof of malignancy. Features suggesting prostate cancer A hard, nodular or irregular prostate on DRE requires suspected cancer pathway referral. A PSA above the relevant referral threshold can also require urgent specialist assessment. Persistent bone pain, particularly spinal or pelvic pain, and unexplained weight loss raise concern about advanced disease. Visible haematuria requires assessment for bladder and kidney cancer as well as prostate disease. Prostatitis and urinary infection Prostatitis can cause pelvic pain, painful urination, fever, ejaculation pain and raised PSA. Urinary infection can cause frequency, urgency, dysuria, cloudy urine and systemic illness. Acute bacterial prostatitis can cause urinary retention and sepsis and requires prompt antibiotic assessment. PSA testing during acute infection can mislead and is not used to diagnose prostatitis. Urethral stricture A urethral stricture is scar related narrowing within the urethra. It can cause weak flow, spraying, straining, incomplete emptying and recurrent infection. Risk factors include previous instrumentation, pelvic injury, infection and urethral surgery. Cystoscopy or urethral imaging may be required when the history suggests a stricture. Overactive bladder Overactive bladder causes urgency, usually with frequency and nocturia, with or without urgency incontinence. It can coexist with BPE or occur without any prostate obstruction. Bladder training and selected bladder medicines may help when storage symptoms dominate. Residual urine and retention risk are considered before adding medicines that reduce bladder contraction. Diabetes and neurological disease High blood glucose can cause excessive urine production and urinary frequency. Diabetes can also damage bladder nerves, producing weak contraction and incomplete emptying. Parkinson's disease, multiple sclerosis, spinal disease and stroke can alter bladder storage or voiding. Neurological warning signs require assessment beyond a routine BPE pathway. Watchful waiting Mild or non bothersome uncomplicated symptoms often need no immediate medicine or procedure. Watchful waiting includes explanation, lifestyle advice, symptom review and clear safety netting. The person can choose treatment later if symptoms become more intrusive or complications develop. Observation should not mean ignoring visible blood, retention, infection or renal impairment. Fluid timing Adequate hydration remains important for kidney health, infection prevention and bowel function. Reducing large drinks before bedtime or long journeys can improve nocturia and urgency. Fluid intake should be spread through the day rather than severely restricted. Excessive restriction can cause dehydration, constipation, concentrated urine and infection risk. Caffeine and alcohol Caffeine can increase urine production and worsen bladder urgency in susceptible people. Coffee, tea, cola, energy drinks and some pain medicines contribute to total caffeine intake. Alcohol can increase urine production and reduce awareness of bladder signals. Gradual reduction can identify whether these substances are materially worsening symptoms. Bladder training Bladder training gradually increases the interval between planned toilet visits when storage symptoms dominate. It helps reduce habitual frequent voiding and improve confidence postponing urgency. Training should be supervised or supported when symptoms are substantial. It is less effective than outlet surgery when proven obstruction is the main problem. Double voiding and urethral milking Double voiding means waiting briefly after urinating and attempting to pass urine again without forceful straining. It can help some people reduce residual urine or the sensation of incomplete emptying. Urethral milking gently moves retained urine forwards after voiding to reduce post micturition dribble. These techniques support symptoms but do not remove significant obstruction. Constipation and general measures Constipation can increase pelvic pressure and worsen urgency or difficulty emptying. Fibre, movement and adequate fluids can support regular bowel function. Weight management and physical activity can improve overall health and may reduce some urinary symptoms. Sleep apnoea, leg swelling and diabetes require treatment when they contribute to nocturia. Reviewing other medicines A clinician or pharmacist can identify medicines worsening frequency, retention or night time urine production. Diuretic timing can sometimes be adjusted without stopping essential cardiovascular treatment. Decongestants and strongly anticholinergic medicines may require alternatives in people vulnerable to retention. Prescribed medicines should not be stopped independently because the underlying condition may deteriorate. When medicine is offered NICE recommends drug treatment for bothersome LUTS when conservative options are unsuccessful or unsuitable. Choice depends on symptom pattern, prostate size, progression risk, blood pressure and sexual priorities. The clinician also considers interactions, falls risk, cataract surgery and previous treatment response. Medication is reviewed rather than continued indefinitely without evidence of benefit. Alpha blockers Alpha blockers relax smooth muscle within the prostate and bladder neck, reducing dynamic outlet resistance. They can improve flow and symptoms within days or weeks but do not shrink the prostate. NICE recommends an alpha blocker for moderate to severe LUTS. Options include tamsulosin, alfuzosin, doxazosin and terazosin. Tamsulosin Tamsulosin selectively blocks alpha 1 receptors that influence prostate and urethral smooth muscle tone. Reduced tension allows urine to pass more easily through the prostatic urethra. It often improves voiding symptoms relatively quickly but does not reduce future prostate growth. Response is reviewed after approximately four to six weeks. Alpha blocker adverse effects Alpha blockers can cause dizziness, weakness and postural hypotension when standing. Fainting risk matters particularly in older people, those taking blood pressure medicines and people prone to falls. Tamsulosin can cause reduced, absent or altered ejaculation, including ejaculation into the bladder. Headache and nasal symptoms can also occur. Tamsulosin and cataract surgery Tamsulosin is associated with intraoperative floppy iris syndrome during cataract surgery. Anyone taking or previously exposed to tamsulosin should inform the ophthalmology team before surgery. The eye surgeon can plan appropriate precautions when the exposure is known. Tamsulosin should not be stopped for eye surgery without advice because the benefit of stopping remains uncertain. 5 alpha reductase inhibitors Finasteride and dutasteride reduce conversion of testosterone into dihydrotestosterone within prostate tissue. This gradually reduces prostate volume and lowers the risk of acute retention and BPE related surgery. NICE recommends them for higher progression risk, including an estimated prostate above 30 grams or PSA above 1.4 ng/ml. They are less useful when the prostate is small and immediate symptom relief is the priority. Delayed benefit from finasteride or dutasteride Some improvement can occur earlier, but a meaningful response may require six months or longer. The prostate usually shrinks gradually rather than changing within days. An alpha blocker may provide earlier relief while the 5 alpha reductase inhibitor takes effect. Review occurs after approximately three to six months and then every six to twelve months. 5 alpha reductase inhibitor adverse effects Possible adverse effects include reduced libido, erectile dysfunction and ejaculation difficulties. Breast tenderness or enlargement can occur, while any breast lump or nipple discharge requires review. Fertility and semen changes can matter to people planning conception. Benefits and sexual effects should be discussed before treatment rather than discovered unexpectedly. Psychiatric and persistent sexual effects The MHRA warns that finasteride is associated with low mood, depression, suicidal thoughts and sexual dysfunction. Sexual dysfunction has sometimes persisted after finasteride was stopped. Dutasteride now carries precautionary class related information about mood changes and sexual effects. New depression, suicidal thinking or troublesome sexual dysfunction requires prompt discussion with the prescriber. How finasteride and dutasteride affect PSA Finasteride and dutasteride lower mean PSA concentrations by approximately 50 percent after about six months. A new PSA baseline should be established once treatment has produced this expected reduction. Clinicians commonly double a stable measured PSA when comparing it with untreated reference thresholds. Any confirmed rise from the new lowest level requires evaluation, even when the absolute result appears normal. Why the PSA correction matters A PSA of 2 ng/ml during established 5 alpha reductase treatment can correspond roughly to 4 ng/ml without treatment. Failing to adjust interpretation can create false reassurance and delay cancer investigation. The approximate doubling rule does not replace review of previous results, adherence and the individual trend. The laboratory and clinician must know which prostate medicines the person is taking. Combination therapy NICE advises considering an alpha blocker plus a 5 alpha reductase inhibitor for selected people. Combination therapy suits bothersome moderate to severe LUTS with a larger prostate or higher progression risk. The alpha blocker provides earlier relaxation, while the 5 alpha reductase inhibitor gradually reduces prostate size. The increased likelihood of dizziness and sexual adverse effects must be balanced against greater long term benefit. Treating persistent storage symptoms Storage symptoms may continue after an alpha blocker improves urine flow. NICE advises considering an antimuscarinic medicine alongside the alpha blocker in selected people. Beta 3 agonists are alternatives when antimuscarinics are unsuitable, ineffective or poorly tolerated. Retention risk, residual urine, dry mouth, constipation, blood pressure and cognitive vulnerability influence selection. When specialist referral is needed Referral is appropriate when bothersome symptoms persist despite conservative and drug treatment. Recurrent infection, urinary retention, suspected renal impairment and possible urological cancer require specialist assessment. A high residual volume, bladder stones or recurrent bleeding can also change management. People considering a procedure need detailed discussion of anatomy, benefits, adverse effects and retreatment risk. When surgery is considered Surgery is usually considered when voiding symptoms are severe or less invasive treatment has failed. It may also be needed for recurrent retention, obstructive kidney impairment, bladder stones or repeated infection. The prostate's size and shape influence which operation is technically suitable. Sexual function, anticoagulant treatment, anaesthetic risk and recovery priorities also matter. Transurethral resection of the prostate Transurethral resection of the prostate, or TURP, removes obstructing tissue through an instrument passed along the urethra. It is a long established reference operation against which many newer treatments are compared. TURP usually produces substantial improvement in flow and symptom scores. Possible complications include bleeding, infection, temporary catheterisation, urethral scarring and urinary incontinence. Sexual effects of TURP Retrograde or absent forward ejaculation is common after TURP because semen enters the bladder during orgasm. Orgasm can remain pleasurable, but little or no semen leaves through the penis. Erectile dysfunction is less common than ejaculatory change but remains a possible complication. Fertility and sexual priorities should be discussed before consent. Other established operations Holmium laser enucleation of the prostate, or HoLEP, removes obstructing lobes using laser energy. It is effective across a wide range of prostate sizes when performed by an experienced service. Transurethral incision can suit selected smaller prostates by opening the bladder outlet without extensive tissue removal. Very large prostates may occasionally require simple prostatectomy through open or minimally invasive surgery. UroLift UroLift places small implants that hold obstructing prostate tissue away from the urethra. NICE supports it for selected people aged 50 or older with suitable prostate size and anatomy. It can preserve ejaculation more reliably than tissue removing operations and is often performed without overnight admission. Symptom improvement may be smaller and retreatment more likely than after some established operations. Rezūm water vapour treatment Rezūm injects controlled steam into obstructing prostate tissue, which gradually shrinks during healing. NICE supports it for selected people with moderate to severe symptoms and a moderately enlarged prostate. It is minimally invasive and has a relatively low risk of sexual dysfunction. Temporary catheterisation and irritative urinary symptoms can occur while swelling settles. Water jet ablation Transurethral water jet ablation, often called Aquablation, uses image guided high pressure water to remove prostate tissue. NICE considers the evidence sufficient for use with standard governance, consent and outcome auditing. It can treat selected moderate to severe obstruction and may preserve ejaculation better than TURP in some groups. Bleeding, anaesthesia, prostate anatomy and local expertise remain important considerations. Prostate artery embolisation Prostate artery embolisation blocks selected arteries supplying the prostate, causing gradual shrinkage. NICE considers the procedure suitable under standard governance when a urologist and interventional radiologist select patients together. It avoids transurethral tissue removal and may suit selected people seeking less invasive treatment. Results, retreatment risk and eligibility vary with arterial anatomy and local expertise. Choosing among procedures No procedure is best for every prostate size, shape, symptom pattern or personal priority. Established tissue removing operations often provide stronger and more durable relief. Some minimally invasive approaches offer shorter recovery or better preservation of ejaculation but may require later retreatment. Shared decision making should compare realistic outcomes rather than presenting every newer treatment as superior. Monitoring after treatment Follow up assesses symptom change, quality of life, adverse effects and new complications. Alpha blockers are usually reviewed after four to six weeks, then every six to twelve months. 5 alpha reductase inhibitors are reviewed after three to six months, then every six to twelve months. A worsening PSA trend, retention or new haematuria requires reassessment outside the routine schedule. Managing acute urinary retention Acute retention requires immediate catheter drainage rather than waiting for tablets to work. An alpha blocker is usually offered before a planned trial without the catheter. The trigger, infection risk, renal function and suitability for future procedural treatment are assessed. Repeated failed catheter removal often leads to more definitive specialist management. Managing chronic retention and obstructive uropathy Chronic retention with a very large residual volume requires creatinine testing and upper urinary tract imaging. Hydronephrosis or impaired renal function caused by retention requires catheter drainage. Intermittent catheterisation can be preferable to long term indwelling catheterisation when practical and safe. Bladder recovery may remain incomplete when obstruction has caused longstanding muscle damage. Visible haematuria Visible blood in urine should not be attributed automatically to an enlarged prostate. Unexplained visible haematuria without infection, or persisting after infection treatment, requires urgent assessment. Under NICE NG12, people aged 45 or older meeting this pattern enter suspected bladder and renal cancer pathways. PSA and DRE may also be considered because prostate disease can coexist. Bone pain and weight loss Persistent unexplained bone pain, particularly in the back, pelvis or hips, can indicate advanced prostate cancer. Unexplained weight loss, reduced appetite and progressive fatigue increase concern when combined with prostate findings. These symptoms are not expected consequences of uncomplicated BPE. Prompt cancer assessment is required even when longstanding urinary symptoms previously appeared benign. Spinal cord compression warning signs Prostate cancer spreading to the spine can rarely compress the spinal cord or cauda equina. New leg weakness, difficulty walking, saddle numbness or loss of bladder or bowel control is an emergency. These symptoms require immediate hospital assessment and should not be confused with ordinary prostate related retention. Rapid treatment can reduce the risk of permanent neurological damage. The central safety message BPE is non cancerous and does not become prostate cancer, although both conditions can coexist. LUTS require assessment because prostate size alone cannot identify the cause, severity or complication risk. PSA supports decision making but can produce false positive and false negative results and requires informed interpretation. Acute retention, visible haematuria, cancer warning signs and obstructive kidney impairment require urgent assessment.

Benign prostatic enlargement can obstruct urine flow and alter bladder function, but urinary symptoms do not prove BPE or exclude cancer. Care combines structured assessment, informed PSA decisions, lifestyle measures, appropriate medicines and selected procedures, with urgent escalation for retention, haematuria, renal impairment or cancer warning signs.